OTCMKTS:OPHLY

Ono Pharmaceutical Stock Forecast, Price & News

$8.94

-0.24 (-2.61 %)

(As of 02/26/2021 10:07 PM ET)

Add

Compare

Today's Range

$8.92

Now: $8.94▼

$9.24

50-Day Range

$9.18

MA: $9.79▼

$10.28

52-Week Range

$5.25

Now: $8.94▼

$10.93

Volume3,800 shs

Average Volume30,950 shs

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.

Headlines

Ribon Therapeutics Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop and Commercialize RBN-2397 In Japan, South Korea, Taiwan and ASEAN Countries
February 2, 2021 | businesswire.com

Forty Seven Wins Exclusive License Deal For 5F9
July 11, 2019 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceuticals: Other

Sub-IndustryN/A

SectorHealth Technology

Current SymbolOTCMKTS:OPHLY

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.ono.co.jp

Phone(166) 263-5670

Employees3,560

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.48 out of 5 stars

Health Technology Sector

16th out of 19 stocks

Pharmaceuticals: Other Industry

4th out of 6 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Ono Pharmaceutical.

2.4 Community Rank

Outperform Votes
Ono Pharmaceutical has received 45 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ono Pharmaceutical has received 50 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ono Pharmaceutical has received 52.63% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ono Pharmaceutical and other stocks. Vote “Outperform” if you believe OPHLY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OPHLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ono Pharmaceutical does not currently pay a dividend.
Dividend Growth
Ono Pharmaceutical does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ono Pharmaceutical insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$8.94

-0.24 (-2.61 %)

(As of 02/26/2021 10:07 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive OPHLY News and Ratings via Email

Sign-up to receive the latest news and ratings for OPHLY and its competitors with MarketBeat's FREE daily newsletter.

Ono Pharmaceutical (OTCMKTS:OPHLY) Frequently Asked Questions

Is Ono Pharmaceutical a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ono Pharmaceutical in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ono Pharmaceutical stock.
View analyst ratings for Ono Pharmaceutical or view top-rated stocks.

What stocks does MarketBeat like better than Ono Pharmaceutical?

Wall Street analysts have given Ono Pharmaceutical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ono Pharmaceutical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a drop in short interest during the month of February. As of February 12th, there was short interest totaling 100 shares, a drop of 95.7% from the January 28th total of 2,300 shares. Based on an average trading volume of 205,700 shares, the days-to-cover ratio is presently 0.0 days.
View Ono Pharmaceutical's Short Interest.

How has Ono Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Ono Pharmaceutical's stock was trading at $6.45 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OPHLY stock has increased by 38.6% and is now trading at $8.94.
View which stocks have been most impacted by COVID-19.

Who are Ono Pharmaceutical's key executives?

Ono Pharmaceutical's management team includes the following people:

Mr. Gyo Sagara, CEO, Pres & Representative Director
Mr. Shozo Matsuoka, Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA
Yukio Tani, Corp. Exec. Officer & Head of Corp. Communications
Mr. Hiroshi Ichikawa, Corp. Sr. Exec. Officer and Exec. Director of Sales & Marketing
Mr. Isao Ono, Exec. Officer, Director of Corp. Research & Director
Mr. Hiroshi Awata, VP, Exec. Officer, Tokyo Branch Head & Director
Mr. Toichi Takino, Exec. Officer, Exec. Director of Discovery & Research and Director
Mr. Toshihiro Tsujinaka, Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director
Kiyoaki Idemitsu, Corp. Exec. Officer & Exec. Director of Clinical Devel.
Shinji Takai M.D., Corp. Officer, Head of Medical Affairs & Head of Data Strategy

Who are some of Ono Pharmaceutical's key competitors?

Some companies that are related to Ono Pharmaceutical include Daiichi Sankyo (DSNKY), ePlus (PLUS), Medipharm Labs (MLCPF), OTCMKTS:WDEXF (WDEXF) and Otsuka (OTSKF).
View all of OPHLY's competitors.

What is Ono Pharmaceutical's stock symbol?

Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLY."

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ono Pharmaceutical's stock price today?

One share of OPHLY stock can currently be purchased for approximately $8.94.

How many employees does Ono Pharmaceutical have?

Ono Pharmaceutical employs 3,560 workers across the globe.

What is Ono Pharmaceutical's official website?

The official website for Ono Pharmaceutical is www.ono.co.jp.

How can I contact Ono Pharmaceutical?

The company can be reached via phone at (166) 263-5670.

This page was last updated on 3/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here